Cabozantinib-related posterior reversible encephalopathy syndrome
Rev Neurol (Paris)
.
2022 Sep;178(7):746-749.
doi: 10.1016/j.neurol.2022.01.010.
Epub 2022 Apr 30.
Authors
L Khatib
1
,
A Cuenant
2
,
D Renard
3
Affiliations
1
Department of Neurology, CHU de Nîmes, université de Montpellier, Nîmes, France.
2
Institut de cancérologie du Gard, CHU de Nîmes, université de Montpellier, Nîmes, France.
3
Department of Neurology, CHU de Nîmes, université de Montpellier, Nîmes, France. Electronic address: dimitri.renard@chu-nimes.fr.
PMID:
35504737
DOI:
10.1016/j.neurol.2022.01.010
No abstract available
Publication types
Letter
MeSH terms
Anilides
Humans
Posterior Leukoencephalopathy Syndrome* / chemically induced
Posterior Leukoencephalopathy Syndrome* / diagnosis
Pyridines / adverse effects
Substances
Anilides
Pyridines
cabozantinib